IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma

Monday, October 16, 2023 1 min read

Key Takeaway: IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma

Full Press Release Details

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma.